In re Prandin Direct Purchaser Antitrust Litigation

Summary of Case and Settlement:

In re Prandin Direct Purchaser Antitrust Litigation (E.D. Mich.). The direct purchaser plaintiffs allege that defendants Novo Nordisk A/S and Novo Nordisk, Inc. engaged in a scheme to unlawfully block generic competition for the diabetes drug Prandin® (repaglinide). In its August 27, 2010 order, the court designated the firm as Co-Lead and Liaison Counsel. On January 20, 2015 the court granted final approval to a $19 million settlement.  

Contact Us

First Name

Last Name

E-mail

Phone

Case This Inquiry Relates To

Comments